Home > Insider Trading > Filing (0001596783-22-000075)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1596783	Catalent Inc.	CTLT	Pharmaceutical Preparations (2834)	208737688

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1862832	Ricky Hopson	C/O Catalent, Inc. 14 Schoolhouse Road Somerset NJ 08873	Pres, Clinical Dev & Supply	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2022-07-26	312	$106.90	17,035	No	4	S	Direct
Common Stock	Acquisiton	2022-07-26	651	$0.00	17,686	No	4	A	Direct
Common Stock	Disposition	2022-07-27	591	$107.67	17,095	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Options to purchase Common Stock	Acquisiton	2022-07-26	2,828	$0.00	2,828	$107.63

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2,828		2032-07-26	No	4	A	Direct

Footnotes

Shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units received pursuant to the Issuer's long-term incentive plan. No shares were withheld by or surrendered to the Issuer.
Includes restricted stock units.
The number of securities reported reflects the acquisition since August 30, 2021 of 274 shares of the Issuer's common stock pursuant to the Issuer's Employee Stock Purchase Plan in transactions exempt from Section 16(b).
Restricted stock units (RSUs) received by the reporting person pursuant to the Issuer's annual grant to executive officers and other personnel under its long-term incentive plan. Each RSU represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur three (3) years from the date of award.
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in order to implement a plan of financial diversification.
Received by the reporting person pursuant to the Issuer's annual grant to executive officers and other personnel under its long-term incentive plan.
The options vest and become exercisable in four equal annual installments beginning on July 26, 2023.